| |
|
|
|
Akari Therapeutics
|
|
4.54 +0.22 (+5.09%) |
10/20/2017 4:00pm |
|
Open: |
4.40 |
Pre close: |
4.32 |
Target:
|
10.55
|
|
High: |
4.65 |
Low: |
4.37 |
Resistance:
|
9.04
11.95
|
|
Volume: |
277,266 |
Market Cap: |
53.46M |
Support:
|
4.32
3.59
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.25
 |
MACD |
MACD(12,26):
|
-0.12 |
|
MA(20): |
6.13 |
Signal(12,26,9): |
0.19 |
|
MA(100): |
4.98 |
Stochastic Oscillator |
%K(14,3):
|
1.77 |
|
MA(250): |
7.27 |
%D(3): |
9.27 |
|
Average Volume(K) |
3-Month: |
38797
|
52-Week |
High:
|
22.20 |
|
10-Days: |
28448 |
Low: |
3.18 |
|
RSI |
RSI(14):
|
40.22  |
Change(%): |
-44.6 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.000 |
Return on Equity (ttm) |
-68.1 |
Shares Out. (M) |
11.00 |
|
EPS Est. Current Year |
-2.360 |
Return on Assets (ttm) |
-43.9 |
Shares Float (M) |
3.71 |
|
EPS Est. Next Year |
-3.110 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.51 |
|
EPS Est. Next Quarter |
-0.690 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
26.57 |
|
Forward EPS |
-1.411 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
85 |
|
Book Value (p.s.) |
1.940 |
EBITDA (p.s.) |
-2.860 |
P/E |
-2.27 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.34 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-25.36 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-23.58 |
P/CF |
-1.97 |
|
|
|
|
|
|
|
